Literature DB >> 26040753

UFM1 Protects Macrophages from oxLDL-Induced Foam Cell Formation Through a Liver X Receptor α Dependent Pathway.

Qi Pang1, Jie Xiong, Xiao-Lei Hu, Jiang-Ping He, Hui-Fang Liu, Guang-Ya Zhang, Yuan-Yuan Li, Feng-Ling Chen.   

Abstract

AIM: Macrophage foam cell formation is the most prominent characteristic of the early stages of atherosclerosis. Ubiquitin Fold Modifier 1 (UFM1) is a new member of the ubiquitin-like protein family, and its underlying mechanism of action in macrophage foam cell formation is poorly understood. Our current study focuses on UFM1 and investigates its role in macrophage foam cell formation.
METHODS: Using real-time quantitative PCR (qRT-PCR) and western blot analysis, we first analyzed the UFM1 expression in mouse peritoneal macrophages (MPMs) from ApoE-/- mice in vivo and in human macrophages treated with oxLDL in vitro. Subsequently, the effects of UFM1 on macrophages foam cell formation were determined by Nile Red staining and direct lipid analysis. We then examined whether UFM1 affects the process of lipid metabolism in macrophages. Lastly, with the method of small interfering RNA (siRNA), we delineated the mechanism of UFM1 to attenuate lipid accumulation in THP-1 macrophages.
RESULTS: UFM1 is dramatically upregulated under atherosclerosis conditions both in vivo and in vitro. Moreover, UFM1 markedly decreased macrophage foam cell formation. Mechanistic studies revealed that UFM1 increased the macrophage cholesterol efflux, which was due to the increased expression of ATP-binding cassette transporters A1 (ABCA1) and G1 (ABCG1). Furthermore, the upregulation of ABCA1 and ABCG1 by UFM1 resulted from liver X receptor α (LXRα) activation, which was confirmed by the observation that LXRα siRNA prevented the expression of ABCA1 and ABCG1. Consistent with this, the UFM1-mediated attenuation of lipid accumulation was abolished by such inhibition.
CONCLUSIONS: Taken together, our results showed that UFM1 could suppress foam cell formation via the LXRα-dependent pathway.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26040753     DOI: 10.5551/jat.28829

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  6 in total

Review 1.  The UFMylation System in Proteostasis and Beyond.

Authors:  Yannis Gerakis; Michaela Quintero; Honglin Li; Claudio Hetz
Journal:  Trends Cell Biol       Date:  2019-11-06       Impact factor: 20.808

2.  Comparing GWAS Results of Complex Traits Using Full Genetic Model and Additive Models for Revealing Genetic Architecture.

Authors:  Md Mamun Monir; Jun Zhu
Journal:  Sci Rep       Date:  2017-01-12       Impact factor: 4.379

3.  Quantification of sterol-specific response in human macrophages using automated imaged-based analysis.

Authors:  Deborah L Gater; Namareq Widatalla; Kinza Islam; Maryam AlRaeesi; Jeremy C M Teo; Yanthe E Pearson
Journal:  Lipids Health Dis       Date:  2017-12-13       Impact factor: 3.876

4.  Ufm1 inhibits LPS-induced endothelial cell inflammatory responses through the NF-κB signaling pathway.

Authors:  Yuan-Yuan Li; Guang-Ya Zhang; Jiang-Ping He; Dan-Dan Zhang; Xiang-Xin Kong; Hui-Min Yuan; Feng-Ling Chen
Journal:  Int J Mol Med       Date:  2017-04-07       Impact factor: 4.101

5.  Indispensable role of the Ubiquitin-fold modifier 1-specific E3 ligase in maintaining intestinal homeostasis and controlling gut inflammation.

Authors:  Yafei Cai; Guangxun Zhu; Siyang Liu; Zezheng Pan; Michaela Quintero; Candace J Poole; Chunwan Lu; Huabin Zhu; Bianca Islam; Jan van Riggelen; Darren Browning; Kebin Liu; Richard Blumberg; Nagendra Singh; Honglin Li
Journal:  Cell Discov       Date:  2019-01-29       Impact factor: 10.849

6.  Ubiquitin-Fold Modifier-1 Participates in the Diabetic Inflammatory Response by Regulating NF-κB p65 Nuclear Translocation and the Ubiquitination and Degradation of IκBα.

Authors:  Xiaolei Hu; Hengyan Zhang; Langen Zhuang; Guoxi Jin; Qingqing Yang; Min Li; Weihua Sun; Fengling Chen
Journal:  Drug Des Devel Ther       Date:  2020-02-25       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.